Comparative Study Shows Differences Between Letrozole and Tamoxifen on Breast Cancer Recurrence Risk
Published: 2005-01-31 06:59:00
Updated: 2005-01-31 06:59:00
The results from a recent clinical trial conducted by the Breast International Group show that Novartis' breast cancer treatment Femara (active ingredient: letrozole) provides better post-surgery protection against breast cancer recurrence than tamoxifen, the current primary therapy.
Accordin...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
